Merrill Lynch Reaffirms Their Hold Rating on Tesaro (TSRO)


In a report released today, Tazeen Ahmad from Merrill Lynch maintained a Hold rating on Tesaro (NASDAQ: TSRO), with a price target of $38. The company’s shares opened today at $36.12, close to its 52-week low of $25.62.

According to TipRanks.com, Ahmad is a 4-star analyst with an average return of 16.2% and a 47.8% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Seres Therapeutics, and MyoKardia Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tesaro with a $54.27 average price target, implying a 50.2% upside from current levels. In a report issued on September 5, Raymond James also maintained a Hold rating on the stock with a $35 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $129.64 and a one-year low of $25.62. Currently, Tesaro has an average volume of 2.17M.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.

Read More on TSRO:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts